OXFORD, UK - Oxford BioDynamics Plc (AIM:OBD), a biotechnology company specializing in precision clinical diagnostics, has announced the accreditation of its Oxford lab by the United Kingdom (TADAWUL:4280) Accreditation Service (UKAS). The lab has met the ISO 15189 standard, which is necessary for clinical testing in the UK.
The accreditation allows the Oxford facility to process orders for the EpiSwitch Checkpoint Inhibitor Response Test (CiRT) and Prostate Cancer Detection Test (PSE) within the UK, which is expected to significantly reduce the turnaround time for test results to 3-5 days.
OBD’s COO, Thomas Guiel, emphasized the accreditation’s role in ensuring high-quality and timely diagnostic testing to support healthcare providers and patients in the UK and Europe. The validation of CiRT as a clinical test in the UK lab marks an important step for OBD’s British partners and customers, including Bupa UK, which covers EpiSwitch CiRT for its customers.
The EpiSwitch platform, on which the tests are based, enables the screening, evaluation, validation, and monitoring of biomarkers for diagnosing patients or determining their response to diseases or treatments. CiRT, in particular, is a stratification tool designed to help clinicians identify patients likely to respond to immune checkpoint inhibitors, a class of immunotherapies.
The successful validation of CiRT in the UK completes OBD’s strategy to implement clinical testing operations at its UK base, which was commissioned in April 2024. This milestone is expected to enhance the availability and efficiency of cancer diagnostics in the region.
Oxford BioDynamics is known for its EpiSwitch 3D genomics platform, which has been utilized to develop clinical diagnostic tests for various diseases. The company’s commitment to advancing personalized healthcare is reflected in its ongoing efforts to introduce precise and sensitive tests for life-changing diseases.
This news is based on a press release statement from Oxford BioDynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.